| Preclinical A Next-Generation
Cancer Treatment |
| Although CAR T-cell therapy has been in development for more than a decade, researchers and healthcare professionals are just now understanding the power of this therapeutic advancement and how to leverage it across many different types of cancers. Even with outstanding results, this forward-thinking treatment doesn't come without challenges and can be a risky undertaking. |
What Should be Considered When Developing a CAR T-Cell Therapy? While this treatment could significantly benefit many patients with even the most rare forms of cancer, it is a complex, expensive therapy with a lot to consider from the start. Before embarking on the development of a CAR T-cell program, check out these guidelines to ensure proper preclinical study design, uncover efficiencies and identify toxicity. Identify the type of cancer model you plan to treat and ensure growth in an in vivo setting Prepare your CAR T-cell therapy for administration Understand study duration and treatment persistence |
| Free White Paper: Ready your research for success with this free white paper from TD2. There are many factors to consider when developing a CAR T-cell therapy, and this white paper provides guidelines for organizations looking to explore this treatment.
| |
TD2 has been an extremely valuable and flexible partner for CRISPR Therapeutics, performing many CAR T-cell mouse studies across multiple antigen targets in a number of oncology indications.
Dr. Jon Terrett,
Head of Immuno-Oncology Research and Translation
CRISPR Therapeutics |
| Contact Us Ready to get started? If you're seeking a partner who can help set your oncology drug program up for success from the onset, we can help. We specialize in oncology - it's all we do - and our expert team aims to save you time, money and resources. Contact us to get started today. |
| Unmatched Scientific Expertise | Accelerated Development | Committed to Your Goals | Patient-Centered |
|
